MarketPulse

PYRUKYND

3 articles
The Motley FoolThe Motley Fool··Eric Volkman

Agios Pharmaceuticals Surges 13% on Beat Earnings, Expanding Mitapivat Market

Agios Pharmaceuticals surged 13% on strong Q1 earnings, with mitapivat revenue jumping 138% to $20.7M. Company plans supplemental FDA application for sickle cell disease expansion.
AGIOFDA approvalsickle cell disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Agios Pharmaceuticals Eyes Accelerated FDA Approval Path for Mitapivat in Sickle Cell

Agios Pharmaceuticals to report Q1 2026 results April 29 amid FDA accelerated approval pursuit for sickle cell mitapivat and UAE thalassemia approval.
AGIOrare diseasesFDA
The Motley FoolThe Motley Fool··Andy Gould

Agios Insider Sells $82K in Stock, But RSU Vesting—Not Confidence—Tells Real Story

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.
XLVAGIOIHEFDA approvalbiotech